Gujarat Themis Biosyn Quarterly Results for Trading Insights
In 2026, Gujarat Themis Biosyn (GUJTHEM) reported revenue ₹162 Cr and net profit ₹48 Cr. For annual financials, live price and key ratios, visit Gujarat Themis Biosyn share price chart.
GUJTHEM Quarterly Results — Revenue, Profit & EPS Highlights
Gujarat Themis Biosyn latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with GUJTHEM fundamental valuation to assess whether the stock is under or overvalued.
- Revenue of ₹153 Cr in March 2025 (+0.0% vs March 2025, -12.1% vs March 2024)
- Net Profit of ₹49 Cr in March 2025 (+0.0% vs March 2025, -16.9% vs March 2024)
- EBITDA of ₹71 Cr in March 2025 (+0.0% vs March 2025)
- Operating Margin of 46.0% in March 2025 (+0.0pp vs March 2025)
- Earnings Per Share of ₹4.48 in March 2025 (+0.0% vs March 2025)
Gujarat Themis Biosyn Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GUJTHEM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 162 | 153 | 174 | 155 | 119 | 5.9% | - |
| Net Profit (₹ Cr) | 48 | 49 | 59 | 58 | 44 | - | - |
| EBITDA (₹ Cr) | 75 | 71 | 83 | 80 | 62 | - | - |
| EPS (₹) | 4.40 | 4.48 | 40.72 | 39.90 | 30.03 | - | - |
| Operating Margin (%) | 45.0% | 46.0% | 46.0% | 50.0% | 51.0% | - | - |
GUJTHEM Share Price Trend — 1-Year Movement Across Quarterly Results
Gujarat Themis Biosyn 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore GUJTHEM price trends to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GUJTHEM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gujarat Themis Biosyn latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1840.6 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 162.9 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6756.5 | 2,860 | 689 | +7.1% | - | 24.1% | 260.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹151,833.39 Cr | 4572.6 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 397.3 |
|
Cipla
Mar 2026 |
₹113,024.67 Cr | 1413.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.8 |
|
Dr Reddys Laborator…
Mar 2026 |
₹109,104.54 Cr | 1331.4 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 502.4 |
All amounts in ₹ Crores